Feature | May 17, 2012| Dave Fornell

FDA Approves Generic Versions of Blood Thinner Plavix

Generic clopidogrel expected to cut medical costs for cardiac patients

May 17, 2012 — The U.S. Food and Drug Administration (FDA) today approved generic versions of the blood-thinning drug Plavix (clopidogrel), which is expected to have a major impact on the cost to treat patients at risk of heart attack and stroke.

The drug is one of the most widely used pharmaceuticals. Although newer drugs have been introduced to compete against clopidogrel, the agent has remained the No. 1 selling antiplatelet agent. That dominance is expected to become stronger with the drug going generic and slashing its cost.

Dr. Reddy's Laboratories, Gate Pharmaceuticals, Mylan Pharmaceuticals and Teva Pharmaceuticals have gained FDA approval for 300 milligram (mg) clopidogrel. Apotex Corp., Aurobindo Pharma, Mylan Pharmaceuticals, Roxane Laboratories, Sun Pharma, Teva Pharmaceuticals and Torrent Pharmaceuticals have received approval for 75 mg clopidogrel.

Generic drugs approved by FDA are of the same high quality and strength as brand-name drugs. The generic manufacturing and packaging sites must pass the same quality standards as those for brand-name drugs.

The agent helps reduce the risk of heart attack and stroke by making it less likely that platelets in the blood will clump and form clots in the arteries. The agent is also used in conjunction with surgical and interventional coronary disease therapies.

“For people who must manage chronic health conditions, having effective and affordable treatment options is important,” said Keith Webber, Ph.D., deputy director of the Office of Pharmaceutical Science in the FDA’s Center for Drug Evaluation and Research. “The generic products approved today will expand those options for patients.”

One issue with the drug is that up to one-third of patients cannot metabolize it. For this reason, clopidogrel has a boxed warning to alert healthcare professionals and patients that the drug may not work well for those with certain genetic factors. Tests are available to see if a patient will respond or not. For non-responders, newer drugs are available that are metabolized differently.

Clopidogrel also interacts with some medications, especially proton pump inhibitors such as Prilosec (omeprazole) and Nexium (esomeprazole). They can reduce the effect of clopidogrel, leaving a person at greater risk for heart attack and stroke.

For more information: www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/Un...

Related Content

radiation dose in the cath lab
News | Radiation Dose Management| May 02, 2016
May 2, 2016 — Starting at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 annual meeting May
Feature | Business| April 28, 2016 | Dave Fornell
 
Technology | Stents Peripheral| April 27, 2016
Veniti Inc. announced the first successful treatment with the Vici Verto Venous Stent System of a patient suffering...
Auris Surgical Robotics, acquisition, Hansen Medical
News | Robotic Systems| April 26, 2016
Auris Surgical Robotics Inc. and Hansen Medical Inc. announced that they have signed a definitive merger agreement...
Siemens Sensis Vibe, hemodyanamics system

Siemens released the Sensis Vibe hemodyanamics system at ACC.16. The newer system offers better integration of cath lab data into cath lab reports and the electronic medical record (EMR).

Feature | ACC| April 25, 2016 | Jon Brubaker, MBA, RCVT, Tom Watson, BS, RCVT, and Sabrina Newell MS, RCS
There were several trends seen in new cardiovascular technologies showcased on the expo floor at the 2016 American...
Medtronic, Drug-Filled Stent, RevElution Trial results, ACC.16, CE Mark
News | Stents Drug Eluting| April 21, 2016
Medtronic plc announced new clinical data from one of the endpoints in the RevElution Trial for its novel, next-...
statins, heart disease, HOPE-3 trial, intermediate-risk patients, hypertension, ACC.16
News | Pharmaceuticals| April 20, 2016
Lowering cholesterol with statins significantly reduced adverse cardiovascular events in people with average...
Boston Scientific, Fetch 2 aspiration catheter, Class 1 recall
News | Thrombectomy Devices| April 20, 2016
April 20, 2016 — Boston Scientific Corp. announced a U.S.
News | Heart Failure| April 19, 2016
In one of the largest trials ever conducted of heart failure patients with reduced ejection fraction, the...
ischemic postconditioning, STEMI patients, clinical outcomes, ACC.16
News | Cath Lab| April 19, 2016
A large randomized controlled trial of ischemic postconditioning in patients who had experienced ST-segment elevation...
Overlay Init